Table 1.
Kaplan–Meier Estimates of 1-Year Overall Survival Rate by Tumor Type and WHO CNS Grade
| Tumor Type | Glioblastoma, IDH-wildtype | Astrocytoma, IDH-mutant | Oligodendroglioma, IDH-mutant 1p/19q Codeleted | H3 K27M Diffuse Midline Glioma | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WHO CNS Grade | 4 | 2 | 3 | 4 | 2 | 3 | n/a | |||||||
| % | (95CI) | % | (95CI) | % | (95CI) | % | (95CI) | % | (95CI) | % | (95CI) | % | (95CI) | |
| Overall | 53.7 | (52.5–54.9) | 98.0 | (96.1–99.0) | 92.4 | (89.6–94.5) | 76.3 | (70.1–81.3) | 97.9 | (95.9–98.9) | 94.4 | (90.9–96.6) | 55.9 | (44.5–65.8) |
| Sex | ||||||||||||||
| Female | 53.3 | (51.4–55.2) | 98.9 | (95.5–99.7) | 92.3 | (87.5–95.3) | 79.1 | (69.4–86.0) | 99.0 | (96.0–99.8) | 94.5 | (88.9–97.4) | 53.7 | (38.2–66.9) |
| Male | 54.0 | (52.4–55.6) | 97.4 | (94.3–98.8) | 92.5 | (88.6–95.1) | 74.2 | (65.7–80.9) | 96.8 | (93.5–98.5) | 94.2 | (88.8–97.1) | 58.4 | (41.1–72.2) |
| Age at diagnosis, years | ||||||||||||||
| <50 | 76.0 | (72.9–78.7) | 99.4 | (97.6–99.9) | 96.5 | (94.0–98.0) | 84.6 | (76.9–89.9) | 99.0 | (96.8–99.7) | 98.6 | (94.4–99.6) | 56.7 | (44.3–67.3) |
| ≥50 | 50.1 | (48.7–51.4) | 91.8 | (82.6–96.2) | 78.4 | (69.3–85.1) | 66.2 | (55.8–74.6) | 95.3 | (89.8–97.9) | 89.1 | (81.9–93.5) | 50.0 | (18.4–75.3) |
| Maximal tumor dimension, cm | ||||||||||||||
| ≤3 | 57.4 | (54.6–60.1) | 98.7 | (91.0–99.8) | 89.9 | (79.9–95.1) | 74.9 | (56.0–86.6) | 98.3 | (88.6–99.8) | 93.2 | (75.5–98.3) | 86.7 | (56.4–96.5) |
| 3–6 | 53.7 | (51.9–55.4) | 97.4 | (93.3–99.0) | 93.6 | (88.7–96.4) | 76.3 | (67.0–83.3) | 98.1 | (94.2–99.4) | 94.9 | (88.1–97.8) | 52.8 | (36.8–66.5) |
| >6 | 49.5 | (46.1–52.8) | 100.0 | (100–100) | 95.7 | (88.8–98.4) | 85.5 | (70.6–93.2) | 97.4 | (89.9–99.3) | 93.5 | (85.1–97.3) | x | x |
| Therapy | ||||||||||||||
| No Chemo, No RT | 19.2 | (16.8–21.6) | 98.8 | (95.2–99.7) | 69.5 | (53.9–80.7) | 32.3 | (16.8–48.8) | 96.9 | (92.7–98.7) | 68.3 | (44.7–83.5) | x | x |
| Chemo & RT | 63.6 | (62.2–65.0) | 98.0 | (94.9–99.3) | 95.7 | (93.1–97.4) | 87.5 | (81.5–91.7) | 99.5 | (96.5–99.9) | 96.8 | (93.4–98.5) | 59.4 | (44.4–71.6) |
| Extent of resection | ||||||||||||||
| Biopsy-only | 37.1 | (34.8–39.4) | 94.2 | (86.7–97.6) | 78.8 | (68.8–85.9) | 52.9 | (35.0–68.0) | 97.8 | (91.3–99.4) | 85.9 | (69.5–93.9) | 55.1 | (40.4–67.6) |
| STR | 52.6 | (50.5–54.8) | 99.3 | (94.8–99.9) | 95.1 | (90.4–97.5) | 75.2 | (63.9–83.4) | 97.9 | (93.6–99.3) | 92.1 | (84.2–96.2) | 52.6 | (28.7–71.9) |
| GTR | 65.5 | (63.6–67.2) | 98.9 | (95.6–99.7) | 96.1 | (92.3–98.0) | 84.5 | (76.3–90.1) | 97.8 | (94.2–99.2) | 97.8 | (93.4–99.3) | x | x |
| MGMT promoter | ||||||||||||||
| Unmethylated | 51.7 | (49.9–53.6) | 96.3 | (89–98.8) | 90.8 | (83–95.1) | 80.5 | (67.6–88.7) | n/a | n/a | n/a | |||
| Methylated | 62.1 | (59.9–64.2) | 100 | (n/a) | 94.1 | (89–96.9) | 83.7 | (74.4–89.8) | n/a | n/a | n/a |
Abbreviations: Chemo, chemotherapy; CNS, Central nervous system; GTR, gross total resection; n/a, not applicable, too few events; RT, radiotherapy; STR, subtotal resection; WHO, World Health Organization; x, Estimates based on <10 cases were suppressed; 95CI, 95% confidence interval.